Morgan Stanley Downgrades Akoya Biosciences to Equalweight From Overweight, Adjusts PT to $3 From $4
Morgan Stanley Downgrades Akoya Biosciences to Equalweight From Overweight, Adjusts PT to $3 From $4
摩根士丹利將Akoya Biosciences的評級下調至等重，從超重調整目標價爲3美元，而不是4美元。
Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.
登入免費觀看全文
登入/註冊
資訊熱榜
更新時間